Changes in the epidemic trend of meningitis and its vaccination
XU Ying-hua, XU Miao, YE Qiang
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,National Institute for Food and Drug Control, Beijing 102629, China
Abstract：In the past few decades, with the widespread use of vaccines, the serogroups of pathogens causing epidemic cerebrospinal meningitis (ECM) in different countries and regions have also changed. This article reviews the research progress on immunization with meningococcal vaccine, infection population, epidemic trend of ECM in different regions and countries and its mechanism so as to further understand the variations in the epidemic trend and vaccination of ECM and provide references for subsequently developing immunization strategies.
徐颖华, 徐苗, 叶强. 流行性脑脊髓膜炎的流行趋势变化与其疫苗接种[J]. 实用预防医学, 2022, 29(8): 1015-1019.
XU Ying-hua, XU Miao, YE Qiang. Changes in the epidemic trend of meningitis and its vaccination. , 2022, 29(8): 1015-1019.
[1] Pizza M,Bekkat-Berkani R,Rappuoli R. Vaccines against meningococcal diseases[J]. Microorganisms, 2020, 8(10):1521. [2] 夏昕,方明礼,覃迪,等.湖南省新发X群Y群流行性脑脊髓膜炎病例菌株的病原学特征分析[J].实用预防医学, 2021,28(11):1295-1298. [3] Stein-Zamir C, Shoob H, Sokolov I, et al. The clinical features and long-term sequelae of invasive meningococcal disease in children[J]. Pediatr Infect Dis J, 2014,33(7):777-779. [4] Olbrich KJ,Müller D,Schumacher S,et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers[J]. Infect Dis Ther, 2018,7(4):421-438. [5] Global Burden of Disease Collaborative Network. Global burden of disease study 2019 (GBD 2019). Unites States Institute for Health Metrics and Evaluation, Seattle (2019)[EB/OL]. (2020-01-20)[2021-06-07]. http://ghdx.healthdata.org/gbd-2019. [6] Parikh SR,Campbell H,Bettinger JA,et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination[J]. J Infect, 2020,81(4):483-498. [7] WHO. WHO Defeating bacterial meningitis by 2030[EB/OL]. (2020-05-01)[2021-06-07]. https://www.who.int/emergencies/diseases/meningitis/meningitis-2030.pdf. [8] Presa J, Findlow J, Vojicic J, et al. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review[J]. Infect Dis Ther, 2019,8(3):307-333. [9] Sherman AC, Stephens DS. Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies[J]. Expert Rev Vaccines, 2020,19(5):455-463. [10] Dhillon S,Pace D. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix ): a review[J]. Drugs, 2017, 77(17):1881-1896. [11] Xu Y, Li Y, Wang S, et al. Meningococcal vaccines in China[J]. Hum Vaccin Immunother, 2021, 17(7):2197-2204. [12] Parikh SR, Newbold L, Slater S, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment [J]. Lancet Infect Dis, 2017, 17(7): 754-762. [13] Ostergaard L, Lucksinger GH, Absalon J, et al. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults [J]. Vaccine, 2016, 34(12):1465-1471. [14] CDC. Recommended child and adolescent immunization schedule [EB/OL]. (2021-02-12)[2021-06-07].https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#note-mening. [15] Public Health England. Removal of the infant dose of MenC conjugate vaccine given at three months[EB/OL].(2016-03-24)[2021-06-07].https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/512311/2016_MenC_infant_schedule_letter-FINAL__1_.pdf. [16] European Centre for Disease Prevention and Control.Vaccine scheduler[EB/OL].(2020-01-30)[2021-06-07].https://vaccine-schedule.ecdc.europa.eu/. [17] 国家卫生健康委.国家免疫规划疫苗儿童免疫程序(2021年版)[EB/OL]. (2021-02-23)[2021-06-07].http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml. [18] Hellenbrand W,Elias J,Wichmann O,et al. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine[J]. J Infect, 2013,66(1):48-56. [19] Sadarangani M, Scheifele DW, Halperin SA, et al. Investigators of the Canadian immunization monitoring program, ACTive (IMPACT) outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study[J]. Clin Infect Dis, 2015,60(8):e27-35. [20] Ladhani SN,Lucidarme J,Newbold LS,et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009[J]. Emerg Infect Dis. 2012,18(1):63-70. [21] Racoosin JA,Whitney CG,Conover CS,et al. Serogroup Y meningococcal disease in Chicago, 1991-1997[J]. JAMA, 1998, 280(24):2094-2098. [22] 李军宏,吴丹,尹遵栋,等. 2015—2017年中国流行性脑脊髓膜炎流行特征分析[J]. 中华预防医学杂志,2019,53(2):159-163. [23] 李军宏,吴丹,温宁,等. 2015-2019年中国流行性脑脊髓膜炎血清群分布特征[J]. 中国疫苗和免疫,2020,26(3):241-244. [24] Mustapha MM,Harrison LH.Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges[J]. Hum Vaccin Immunother, 2018, 14(5): 1107-1115. [25] Tiffay K, Jodar L, Kiency MP, et al. The evolution of the meningitis vaccine project[J]. Clin Infect Dis, 2015,61(Suppl 5): S396-S403. [26] European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe [EB/OL]. (2011-01-01)[2021-06-11].http://ecdc.europa.eu/en/publications/Publications/invasive-bacterial-diseases-surveillance-2011.pdf. [27] Broker M, Emonet S, Fazio C, et al. Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013[J]. Hum Vaccin Immunother,2015,11(9):2281-2286. [28] Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales[J]. Clin Infect Dis, 2015, 60(4):578-585. [29] System. NNDS disease notification rates, Australia, 1991 to 2018 and year-to-date notifications for 2019. Australian Government Department of Health [EB/OL].(2019-02-01)[2021-06-11].http://www9.health.gov.au/cda/source/rpt_2.cfm. [30] Health AG. Invasive meningococcal disease national surveillance report-with a focus on men-31 March 2018. Australian Government Department of Health [EB/OL].(2018-03-31)[2021-06-11].https://www.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/1Jan-31Mar2018-Consol-Invasive-Men-W.pdf. [31] Wang X, Shutt KA, Vuong JT, et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure[J]. J Infect Dis, 2015, 211(12):1887-1894. [32] MacNeil JR, Blain AE, Wang X, et al. Current epidemiology and trends in meningococcal disease-United States, 1996-2015[J]. Clin Infect Dis, 2018, 66(8):1276-1281. [33] Soeters HM,McNamara LA,Blain AE,et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018[J]. Emerg Infect Dis, 2019,25(3):434-440. [34] Ambur OH, Frye SA, Tnjum T. New functional identity for the DNA uptake sequence in transformation and its presence in transcriptional terminators[J]. J Bacteriol, 2007,189(5):2077-2085. [35] Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis[J]. Proc Natl Acad SciUSA, 1997,94(1):271-276. [36] Guo Q, Mustapha MM, Chen M, et al. Evolution of sequence type 4,821 clonalcomplex meningococcal strains in China, from prequinolone to quinolone era,1972-2013[J]. Emerg Infect Dis,2018,24(4):683-690. [37] Chen M, Harrison OB, Bratcher HB, et al. Evolution of sequence type 4821 clonal complex hyperinvasive and quinolone-resistant meningococci[J]. Emerg Infect Dis, 2021,27(4):1110-1122. [38] Parkhill J, Achtman M, James KD, et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491[J]. Nature, 2000, 404(6777):502-506. [39] Hammerschmidt S,Muller A,Sillmann H,et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease[J]. Mol Microbiol, 1996, 20(6):1211-1220. [40] Bartley SN, Tzeng YL, Heel K, et al. Attachment and invasion of Neisseria meningitidis to host cells is related to surface hydrophobicity, bacterial cell size and capsule[J]. PLoS One, 2013,8:e55798. [41] Dolan-Livengood JM, Miller YK, Martin LE, et al. Genetic basis for nongroupable Neisseria meningitidis[J]. J Infect Dis, 2003,187(10):1616-1628. [42] Uria MJ, Zhang Q, Li Y, et al. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies[J]. J Exp Med, 2008, 205(6):1423-1434.
2022, Vol. 29 
